Abstract
Abstract: Itraconazole (ITZ) has been the mainstay of oral antifungal treatment for the current epidemic of recalcitrant dermatophytosis (RD) in India. Recently, a newer formulation of ITZ, super bioavailable itraconazole (SUBA-ITZ), is made available in the market by many pharmaceutical companies. It is important for dermatologists to understand the pharmacokinetic properties of SUBA-ITZ vis-a-vis conventional pellet formulation to use it effectively and safely. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) has established a special interest group for recalcitrant dermatophytosis (SIG-RD) to strengthen research, continuing medical education, and industry collaboration on the subject. This position statement on SUBA-ITZ by SIG-RD is an attempt to address current pieces of evidence and the position of this new formulation in the management of RD.
Author supplied keywords
Cite
CITATION STYLE
Patel, N. H., Sardana, K., Shenoy, M. M., Rengasamy, M., Khurana, A., Ghate, S., … Jain, A. K. (2024). IADVL SIG Recalcitrant Dermatophytosis Position Statement on Super Bioavailable Itraconazole. Indian Dermatology Online Journal, 15(1), 1–7. https://doi.org/10.4103/idoj.idoj_668_22
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.